Bernstein SocGen Group Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)

Bernstein SocGen Group analyst William Pickering reiterated an Outperform rating and $37.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "Reiterate Outperform. Investors seem to be imposing a higher bar than clinicians. Setup thru ‘25 is tricky given uncertain timing of competitor data. But fast-forward 1 year and we’d still expect on BEAM for the following reasons: additional lung data likely to look good, initial liver data will shed light on editing efficiency, and early data on redosing will hint at commercial product profile (likely just patients started at DL1 but we’d love to see more)."

For an analyst ratings summary and ratings history on Beam Therapeutics Inc click here. For more ratings news on Beam Therapeutics Inc click here.

Shares of Beam Therapeutics Inc closed at $24.01 yesterday.

You May Also Be Interested In

• Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
• Foot traffic at Taco Bell for week of August 3 down 8%, compared to a near 20% decline in mid-July - Placer.AIdata
• Popular stocks with increasing option volume: SPCX MU SMCI INTC AMZN NFLX HTZ MSTR NBIS PLTR SNDK CRWV ORCL CSCO